PDLIM2 and intestinal cancer: Epigenetic inhibition of PDLIM2 leads to reduced expression across various intestinal cancer cell lines, indicating that the loss of PDLIM2 is a significant contributor to NF-κB activation, with epigenetic inhibition being associated with promoter methylation (Qu et al., 2010b).